OCUL vs. EYPT ← (FREE POST)
JNap Podcast

OCUL vs. EYPT ← (FREE POST)

Jul 28, 2026
48:05
-(0)

About this episode

Hello Subs! This (long) podcast covers OCUL’s AXPAXLI vs. EYPT’s DURAVYU ahead of the readout of EYPT’s first-phase 3 study called LUGANO. I provide background on the science, clinical data, endpoints we know (from OCUL’s SOL-1), and endpoints we’re extrapolating based on existing data (to OCUL’s SOL-R and EYPT’s LUGANO/LUCIA studies). I make some predictions and share my assessment of the market. I conclude with thoughts on valuation and how my portfolio is positioned at this time. Cheers! JNap Disclosure: We are Long OCUL, Short EYPT This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit bio5c.substack.com/subscribe

Comments

Rate this episode

Episode Details

Author
JNap
Show Type
full
Audio Format
audio/mpeg

We use analytics

We use Umami, a privacy-friendly analytics tool, to understand how visitors use this site. No personal data is collected and no data leaves our EU servers. You can accept or decline below. Privacy Policy